

**Pharmaceutical Online The Magazine**

 Fall Edition '09  
 Spring Edition '09

**Resource Center**

Single-Use

**Find BioPharm Solutions**

 Assay  
 Assay Development  
 Bioanalytical Methods  
 Biopharmaceutical Contract Manufacturing  
 Bioprocessing  
 Bioreactors  
 Biosafety Cabinet  
 Cell Culture  
 Centrifuge  
 Chemicals  
 Chromatography  
 Cleaning  
 Clinical  
 Columns  
 Contract Manufacturing  
 Contract Services  
 Contract Testing  
 Diagnostics  
 Downstream Processing  
 Equipment Service  
 Fermentation  
 Fill Finish  
 Filtration  
 Filters  
 Formulation  
 Freeze Dryers  
 HPLC  
 Incubator  
 Lab Centrifuge  
 LIMS  
 Media  
 Microbial  
 Monoclonal Antibodies  
 Oligos  
 Outsourcing  
 Peptides  
 Process Development  
 Proteins  
 Purification  
 Quality Issues  
 RNA  
 Separation  
 Single Use  
 Software  
 Stainless Steel Hand Tools  
 Therapeutics  
 Validation  
 Washers

**News and Information**

 Current Headlines  
 White Papers and Case Studies  
 Product Showcase  
 Newsletters  
 Events  
 Market Research Reports  
 Bookstore  
 Industry Associations

**Services**

 Job Search  
 Recruiter Center

**Tools**

 Sign In  
 Free Newsletter

**Advertise Online**


 Media Kit  
 2009 Editorial Calendar  
 Be A Contributor

**Articles**
 Share  RSS

**Increases Effectiveness Of Drugs Used To Fight Cancer And Allows Reduction In Dosage**

November 25, 2009

Researchers at the University of Granada have found a suicide gene, called 'gene E', which leads to the death of tumour cells derived from breast, lung and colon cancer, and prevents their growth. The importance of this new gene is that its use to fight cancer can reduce the potent drugs that are currently used, so that could mean more effective treatment for cancer.



This research was conducted by Ana Rosa Rama Ballesteros, from the Department of Anatomy and Human Embryology at the University of Granada, and directed by professors Antonia Aránega Jimenez, José Carlos Prados Salazar and Consolación Melguizo Alonso. Its aim was to study the possibility of reducing the dosage of drugs currently administered to cancer patients using combination therapy with suicide gene E.

Scientists from the UGR have shown that the bacteriophage phiX174 killer gene called E, can be used to induce death in tumour cells. So far, attempts to use many chemotherapeutic (cytotoxic) agents similar to the E gene have shown severe limitations resulting from their toxicity and their poor affinity with the tumour.

**Advantages of gene therapy**

As Ana Rosa Rama explains, chemotherapy, radiotherapy and surgery show at present "limited" results in advanced stages of cancer. "That is why it is urgent to find new therapies, and gene therapy has emerged as a potentially powerful therapeutic platform." Her work has shown that "it is possible to use gene therapy as an aid to chemotherapy, improving its results when it comes to attacking cancer, thus allowing the dosage of agents to be reduced and contributing to a reduction in side effects for the patient."

In order to understand how the E gene works, the researchers conducted studies using various techniques. The results indicate that the E gene's mechanism of action is to induce apoptosis (cell death), possibly through mitochondrial injury.

Therefore, they stress that "this new E gene appears as an ideal candidate to be transfected into tumour cells in order to induce apoptosis, possibly through mitochondrial activation, and to increase the sensitivity of these cells to the action of the drug developed specifically to act on them."

The results of this research suggest the possibility of reducing the concentration of chemotherapeutic agents in current use with cancer patients. Thus, in lung cancer cell line A-549, scientists from the UGR achieved a 14% inhibition of tumour growth and reduced by 100 times the dose of Paclitaxel agent when it was combined with gene E. In the case of colon cancer, the results were similar. However, the most relevant fact was found in the breast cancer cell line MCF-7, in which the dose of the chemotherapeutic agent, doxorubicin, was reduced by 100 times, reaching up to a 21% greater inhibition of tumour proliferation when combined with gene E. Currently, researchers from the UGR are in the process of obtaining a patent for gene E.

SOURCE: University of Granada